Clinical Trials
19 trialsNCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03381183 2025-12-05
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03739931 2025-08-15
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
Phase 1 Completed
NCT03635164 2025-06-27
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
University of Colorado, Denver
Phase 1 Completed
NCT03618654 2025-05-15
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03212469 2025-05-08
ABIMMUNE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT06446570 2024-06-06
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
Phase 2 Completed
NCT03723967 2024-04-22
FRAIL-IMMUNE
Centre Leon Berard
Phase 2 Completed
NCT03624231 2023-08-31
DURTRE-RAD
Charite University, Berlin, Germany
Phase 2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03162224 2022-08-25
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Phase 1/2 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT02551159 2021-10-13
KESTREL
AstraZeneca
Phase 3 Completed
NCT03144778 2021-03-18
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01938612 2021-03-12
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02882308 2020-02-07
OPHELIA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT02262741 2017-10-23
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
MedImmune LLC
Phase 1 Completed